TPF+IMRT

PreclinicalSmall molecule

GGuiyang Medical University

TPF+IMRT is one of 50 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

90 competitors in Nasopharyngeal Carcinoma

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 3

7 2

Tuoyi

CCoherus Oncology, Inc.

Phase 3

20 3

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

20 4

Taxotere

AAvyxa

Phase 3

15 5

Tuoyi

SSun Yat-sen University

Phase 3

11 6

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

10 7

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

6 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 3

6 9

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

2 10

Induction Phase1

Genmab

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma1 trial

GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma

Unknown status·GGuiyang Medical University··NCT03723343·146 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TPF+IMRT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TPF+IMRT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TPF+IMRT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guiyang Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGuiyang Medical University

TPF+IMRT

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Nasopharyngeal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News